| Compound Information | SONAR Target prediction |
| Name: | PRAZOSIN HYDROCHLORIDE |
| Unique Identifier: | SPE01500495 |
| MolClass: | Checkout models in ver1.5 and ver1.0 |
| Molecular Formula: | |
| Molecular Weight: | 397.687 g/mol |
| X log p: | 10.65 (online calculus) |
| Lipinksi Failures | 1 |
| TPSA | 75.96 |
| Hydrogen Bond Donor Count: | 0 |
| Hydrogen Bond Acceptors Count: | 9 |
| Rotatable Bond Count: | 5 |
| Canonical Smiles: | Cl.COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1occc1 |
| Source: | synthetic |
| Therapeutics: | antihypertensive |
| Generic_name: | Prazosin |
| Chemical_iupac_name: | [4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2-furyl)methanone |
| Drug_type: | Approved Drug |
| Pharmgkb_id: | PA451093 |
| Kegg_compound_id: | C07368 |
| Drugbank_id: | APRD00020 |
| Melting_point: | 279 oC |
| H2o_solubility: | 0.2 mg/mL (as HCl salt) |
| Logp: | 0.934 |
| Cas_registry_number: | 19216-56-9 |
| Drug_category: | Antihypertensive Agents; Alpha-adrenergic Blocking Agents; ATC:C02CA01 |
| Indication: | For treatment of hypertension and chronic heart failure. |
| Pharmacology: | Prazosin is an alpha-adrenergic blocking agent used to treat hypertension and benign prostatic hyperplasia. Accordingly, Prazosin is a selective inhibitor of the alpha1 subtype of alpha adrenergic receptors. In the human prostate, Prazosin antagonizes phenylephrine (alpha1 agonist)-induced contractions, in vitro, and binds with high affinity to the alpha1c adrenoceptor, which is thought to be the predominant functional type in the prostate. Studies in normal human subjects have shown that Prazosin competitively antagonized the pressor effects of phenylephrine (an alpha1 agonist) and the systolic pressor effect of norepinephrine. The antihypertensive effect of Prazosin results from a decrease in systemic vascular resistance and the parent compound Prazosin is primarily responsible for the antihypertensive activity. |
| Mechanism_of_action: | Prazosin acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation. |
| Organisms_affected: | Humans and other mammals |
| Found: 205 nonactive as graph: single | with analogs | 1 2 3 4 5 6 7 8 9 10 Next >> [205] |
| Species: | 4932 |
| Condition: | BCK1 |
| Replicates: | 2 |
| Raw OD Value: r im | 0.8450±0.0156978 |
| Normalized OD Score: sc h | 1.0075±0.00360325 |
| Z-Score: | 0.4817±0.0789318 |
| p-Value: | 0.630576 |
| Z-Factor: | -3.66198 |
| Fitness Defect: | 0.4611 |
| Bioactivity Statement: | Nonactive |
| ps |
| DBLink | Rows returned: 4 |
| 4893 | [4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2-furyl)methanone |
| 68546 | [4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2-furyl)methanone hydrochloride |
| 450782 | [4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2-furyl)methanone |
| 657274 | [4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2-furyl)methanone; hydrogen(+1) cation; chloride |
| internal high similarity DBLink | Rows returned: 0 |
| active | Cluster 11747 | Additional Members: 10 | Rows returned: 1 |
| LOPAC 01246 | 0.542553191489362 |
Service provided by the
Mike Tyers Laboratory